<a href="https://www.fiercebiotech.com/biotech/bayer-buy-perfuse-300m-upfront-midphase-eye-disease-prospect" hreflang="en">Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect</a>
Bayer has acquired Perfuse Therapeutics for $300 million upfront, with potential milestone payments of up to $2.15 billion, to gain control of the eye disease implant PER-001, which has shown promise in phase 2 trials for glaucoma and diabetic retinopathy. This acquisition aims to enhance Bayer's ophthalmology pipeline, especially as its leading eye drug, Eylea, approaches the end of its lifecycle.
Bayer's acquisition of Perfuse Therapeutics for $2.4 billion highlights the strategic importance of advancing eye disease treatments through innovative drug delivery systems like the PER-001 intravitreal implant. For professionals tracking healthtech and biotech investments, this deal underscores the potential value in mid-phase clinical assets with promising early-stage data, particularly in areas lacking robust late-stage pipelines. Additionally, it signals a growth opportunity in developing treatments that address unmet needs in ophthalmology, such as glaucoma and diabetic retinopathy, where current options may be nearing the end of their lifecycle.